Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares made small gains first thing Wednesday. The biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced an enrollment update on the APOLLO-CD and ARTEMIS-UC trials.
Peometheus has completed enrollment for APOLLO-CD, a global Phase 2a study of PRA023 in Crohn’s Disease (CD) and enrollment remains on track in the Phase 2 study of PRA023 for ARTEMIS-UC in ulcerative colitis (UC) with enrollment completion of cohort 1 expected in the third quarter of this year.
Topline results from both APOLLO-CD and ARTEMIS-UC are expected in the fourth quarter of this year.
“Completing enrollment of APOLLO-CD is a major milestone for the trial and an important achievement for Prometheus given the expeditious speed in the execution of our trials,” said CEO Mark McKenna.
The company also remains on track for implementing its subcutaneous formulation for registrational studies in UC and CD, with an industry-leading subcutaneous formulation of 200 mg/ml.
With Enroll360TM, Prometheus has been building a global network of trial-ready sites where over 2,500 patients have already been genetically profiled and clinically characterized to determine their eligibility for Prometheus’ current and future clinical trials.
Prometheus plans to utilize this patient recruitment platform to accelerate patient identification and increase the rate of enrollment for the company’s biomarker-guided clinical trials, starting with the expansion cohort of the ARTEMIS-UC Phase 2 study.
RXDX shares acquired eight cents to $28.55.
Related Stories
